Screening For B-19 Virus Should Be Limited To Plasma Products - BPAC
This article was originally published in The Gray Sheet
Executive Summary
FDA should not require blood product manufacturers to conduct clinical effectiveness studies or require an investigational new drug exemption for the nucleic acid testing (NAT) of plasma for Parvovirus B-19, members of the agency's Blood Products Advisory Committee agreed at their Sept. 16 meeting in Bethesda, Maryland.
You may also be interested in...
Biden Administration Is Setting An Example For Safe AI Use In Federal Organizations
A new memorandum by the Director of the Office of Management and Budget initiated a government-wide policy that will appoint AI officers to all agencies to address risks for AI use and serve as an example for greater AI adoption.
US FDA Drugs Center Ready To Break Down Silos On Regulatory Innovation
CDER Director Cavazzoni is promising to increase coordination and collaboration to accelerate broader adoption of innovative clinical trial designs and other approaches to speed drug development. A new "Quantitative Medicine Center of Excellence" illustrates the approach.
New OSP Director To Guide CDER-Wide IT Upgrades; System Enhancements Speed ANDA Assessments
Generic Drug Structured Assessment for Bioequivalence launched in 2023 and has been used in 40 ANDA reviews so far.